On July 18, 2020, the Board of Directors of Protagenic Therapeutics, Inc. voted unanimously to Increase the size of the Board from five directors to six directors as permitted under Article II, Section 2 of the Company's Bylaws, and Appoint Jennifer Buell, Ph.D. as a member of the Board, effective immediately, to fill the vacancy created by such increase and to serve until the next annual meeting of shareholders. Dr. Buell serves as the President and Chief Operating Officer of Agenus Inc. Since 2013, Dr. Buell has served Agenus as the Head of Global R&D operations, Head of Research, and Chief External Affairs and Communications Officer.